Cardiome eliminating 85% of staff after Merck deal evaporates

Cardiome's ($CRME) rather vague plans to cut expenses following the loss of a key partnership acquired some cruel clarity today for the biotech's staffers. The developer says it will ax 85% of its sta…
Read the full story: News